Home > Insider Trading > Filing (0000950170-24-110955)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1936258	Newamsterdam Pharma Co N.v.	NAMS	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
2004379	Frederika Louise Kooij	C/O Newamsterdam Pharma Company N.v. Gooimeer 2-35 Naarden P7 1411 DC	Chief Accounting Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2024-09-27	45,000	$0.00	45,000	No	4	M	Direct
Ordinary Shares	Disposition	2024-10-01	45,000	$15.72	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Option (right to buy)	Disposition	2024-09-27	45,000	$0.00	45,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
168,073		2031-07-06	No	4	M	Direct

Footnotes

The exercise price of the option is EUR 1.16392.
The securities were previously held indirectly by the Reporting Person through LouFre Management B.V. ("LouFre") for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities.
The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 60,879 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.